{
    "RADCURE-3757": {
        "recruit-recruiter": "1. Radiation Oncologist - Your expertise is strictly limited to radiation therapy planning and dosing for head and neck cancers, including adenoid cystic carcinoma of the oropharynx. - Hierarchy: Radiation Oncologist",
        "question": "Age: 67.6, Sex: Female, ECOG PS: ECOG 0, Smoking PY: 5, Smoking Status: Ex-smoker, Ds Site: Oropharynx, Subsite: Base of Tongue, T: T4a, N: N0, M : M0, Stage: IVA, Path: Adenoid Cystic, HPV: none, Tx Modality: RT alone, Chemo? : none, Dose: 70.0, Fx: 35, Local: none, Regional: none, Distant: none, 2nd Ca: none, ContrastEnhanced: 1\nAnswer: ",
        "think-initial_assessment-radiation oncologist": "<think> Okay, let me start by going through the patient's details. She's 67.6 years old, female, ECOG PS 0, which means she's fully active. She has a 5-pack-year smoking history but is an ex-smoker. The tumor is in the oropharynx, specifically the base of the tongue, and it's adenoid cystic carcinoma. The staging is T4a, N0, M0, so Stage IVA. HPV status is negative, which is relevant because HPV-positive oropharynx cancers have better prognosis, but since this is adenoid cystic, HPV status might not be as impactful. Treatment was RT alone at 70 Gy in 35 fractions, no chemo. No local, regional, or distant recurrences noted, and no second cancers.\n\nAdenoid cystic carcinoma (ACC) is a salivary gland tumor, known for its indolent growth but high propensity for perineural invasion and late recurrences. Even though it's staged as IVA due to T4a (likely invasion into adjacent structures like the larynx or extrinsic muscles), the N0 and M0 status might suggest a more localized disease. However, ACC can be tricky because it can metastasize late, sometimes years after initial treatment. \n\nRadiation therapy alone is a consideration here. For ACC, surgery followed by adjuvant RT is standard if resectable. But if the tumor is unresectable or the patient isn't a surgical candidate, definitive RT is used. The dose of 70 Gy in 35 fractions is standard for definitive treatment in head and neck cancers. However, ACC's radioresponsiveness is variable. Some studies suggest that higher doses may improve local control, but it's still debated. \n\nGiven that there are no recurrences noted yet, the patient might be in the early follow-up period. However, ACC's tendency for late recurrence (even 10+ years later) complicates survival estimates. Five-year survival rates for ACC of the head and neck vary, but T4 tumors have worse outcomes. Since it's a major salivary gland tumor in the oropharynx, the location might also affect outcomes due to proximity to critical structures. \n\nThe patient's age is a factor, but ECOG 0 is favorable. Smoking history is minimal, but ex-smoker status might not have as much impact here compared to squamous cell carcinomas. Since there's no mention of recurrence or metastases, current status could be alive. But considering the aggressive T4a and the natural history of ACC, long-term survival might be guarded. However, without recurrence data beyond the treatment period, I might lean towards alive if assuming the treatment was recent and effective. Wait, the question doesn't specify the time since treatment. If it's immediately after treatment, then alive. But if it's years later without recurrence, maybe still alive. But ACC can have late metastases. Hmm. \n\nAlternatively, in the absence of recurrence data, maybe the answer is alive, assuming the treatment was successful in controlling the disease. But T4a and ACC's nature could mean higher risk. However, without evidence of recurrence, the default might be alive. I need to balance these factors. The lack of chemo might not be as critical here since ACC is less responsive to chemo anyway. So RT alone with 70 Gy is appropriate. Given all that, the answer is likely Alive.",
        "initial_assessment-radiation oncologist": "Answer:Alive",
        "Round 1-role-comment": "radiation oncologist:alive",
        "Round 1-num_agents": 1,
        "think-Round 2-Turn 1-discuss-participate-radiation oncologist": "<think> Okay, let's break this down. The patient is a 67-year-old female with adenoid cystic carcinoma of the oropharynx, specifically the base of the tongue. The tumor is classified as T4a, N0, M0, stage IVA. She's an ex-smoker with a 5-pack-year history, HPV-negative, and received radiation therapy alone at a dose of 70 Gy in 35 fractions. There's no mention of recurrence locally, regionally, or distantly, and no second primary cancers. The current opinion from the radiation oncologist is 'alive'. \n\nAdenoid cystic carcinoma (AdCC) is known for its indolent growth but high propensity for perineural invasion and late recurrences. Even though it's T4a, the N0 and M0 status might suggest a more localized disease. Radiation therapy alone at 70 Gy is a standard dose for head and neck cancers, especially when surgery isn't feasible. However, AdCC can be radioresistant compared to other carcinomas, which might affect long-term control.\n\nSince the radiation oncologist's opinion is already provided, and the case falls within their expertise, additional input might not be necessary unless there are factors outside their scope. For example, if there were surgical considerations or systemic therapy options, consulting a surgeon or medical oncologist could be beneficial. But in this case, the treatment was RT alone, and there's no indication of complications requiring other specialties. Therefore, the radiation oncologist's assessment suffices.",
        "Round 2-Turn 1-discuss-participate-radiation oncologist": "Answer:Alive",
        "think-Round 2-Turn 1-ask_gap-radiation oncologist": "<think> Okay, let's break this down. The patient has adenoid cystic carcinoma of the oropharynx, specifically the base of the tongue. The stage is IVA (T4a, N0, M0), treated with RT alone at 70 Gy in 35 fractions. The radiation oncologist's opinion is 'Alive'. Now, the question is whether any additional specialists are needed beyond the current team.\n\nAdenoid cystic carcinoma is a salivary gland tumor known for perineural invasion and late recurrences. Even though it's T4a, which might involve adjacent structures, the patient is N0 and M0. Radiation alone was chosen, possibly due to the patient's ECOG 0 status and maybe surgical unresectability or patient choice. \n\nAs a radiation oncologist, I focus on dosing and planning. However, adenoid cystic can sometimes have a protracted course. Considering the treatment modality used, maybe checking if surgery was considered? But that's not my role. Since the team only includes a radiation oncologist, other aspects like surgical evaluation, medical oncology for systemic therapy (though chemo isn't standard here), or ENT for surgical options might be gaps. Also, HPV-negative status in oropharynx typically has worse outcomes, but adenoid cystic is usually HPV-negative anyway. \n\nSince the current team only has a radiation oncologist, input from a head and neck surgeon (ENT) for surgical resectability or a medical oncologist for potential systemic therapy (though not standard) might be needed. Also, pathologists to confirm histology, but that's already done. So yes, additional specialists like ENT or medical oncology could provide input beyond radiation planning.",
        "Round 2-Turn 1-ask_gap-radiation oncologist": "---\nAnswer: yes\nReason: ENT surgeon for surgical resectability assessment\n---",
        "Round 2-Turn 1-gap_identified-assistant": "ENT surgeon for surgical resectability assessment",
        "Round 2-Turn 1-gap_recruit-recruiter": "1. ENT Surgeon - Your expertise is strictly limited to surgical assessment of resectability and operative management of oropharyngeal cancers, including adenoid cystic carcinoma of the base of tongue. - Hierarchy: ENT Surgeon == Radiation Oncologist",
        "think-Round 2-Turn 1-gap_recruited_assessment-ent surgeon": "<think> Okay, let me think through this case step by step. The patient is a 67-year-old female with a history of light smoking (5 pack-years, ex-smoker). She has an adenoid cystic carcinoma of the base of the tongue, which is T4a, N0, M0, stage IVA. The treatment modality was RT alone (70 Gy in 35 fractions), no chemo. Now, considering my role as an ENT surgeon focused on surgical aspects, I need to assess how this relates to resectability and surgical management, which might impact survival.\n\nFirst, adenoid cystic carcinoma (ACC) is a salivary gland tumor known for its indolent growth but high propensity for perineural invasion and late recurrences. Base of tongue location is challenging surgically due to proximity to critical structures like nerves and blood vessels. T4a suggests invasion into adjacent structures (like extrinsic tongue muscles, medial pterygoid, hard palate, or mandible), which may complicate resection. However, since the treatment was RT alone, perhaps the tumor was deemed unresectable or the patient wasn't a surgical candidate. \n\nSurgical resectability in T4a base of tongue tumors often depends on the extent of invasion. If the tumor is resectable, surgery followed by RT is typical. But if it's unresectable (e.g., encasing carotid artery, extensive skull base involvement), then definitive RT or chemoradiation might be chosen. Here, RT alone was used, so maybe the tumor wasn't amenable to surgery. ACCs are generally less responsive to RT compared to squamous cell carcinomas, which might affect outcomes. However, ACCs can have a prolonged course even with residual disease.\n\nN0 and M0 status is favorable. No nodes or distant mets at diagnosis. But ACCs are notorious for late distant metastases, especially to the lungs. The patient's current status shows no local, regional, or distant recurrence. Since ACCs have a 5-year survival that's relatively high, but with recurrence rates over decades, the survival might depend on how long it's been since treatment. The provided data doesn't mention time since treatment, but assuming this is within a few years, the patient might still be alive. However, T4 disease and possible positive margins (if resected) are poor prognostic factors, but here it's treated with RT alone. Radiation dose of 70 Gy is standard, so adequate local control possible.\n\nFrom an ENT surgical perspective, even if the tumor wasn't resected, the absence of recurrence (local/regional/distant) noted here suggests that the RT might have achieved control. However, ACC's tendency for late recurrence means survival could be longer than other cancers, but the stage IVA (T4a) might offset that. But since there's no evidence of progression, maybe alive. However, without surgery, local control rates might be lower. But each case varies. Considering ACC's behavior, even with advanced local stage, survival can be prolonged, so the answer might be Alive.",
        "Round 2-Turn 1-gap_recruited_assessment-ent surgeon": "Answer:Alive",
        "think-Round 2-Turn 1-Round 2-Turn 1-gap_recruited_discuss-participate-ent surgeon": "<think> Okay, let me go through this step by step. The patient is a 67-year-old female with adenoid cystic carcinoma of the base of the tongue, staged T4a N0 M0 IVA. She's an ex-smoker with 5 pack-years. The treatment given was RT alone (70 Gy in 35 fractions) without chemotherapy. The other experts have already provided their opinions, both saying 'Alive'. \n\nAs an ENT surgeon focused on surgical aspects, my role here is to assess resectability and surgical management. Adenoid cystic carcinoma is known for its indolent growth but high propensity for perineural invasion and late recurrences. For base of tongue tumors, T4a indicates invasion into adjacent structures like the larynx or extrinsic muscles. Surgical resection in this area is challenging due to functional implications (speech, swallowing) and proximity to critical structures.\n\nSince the patient received RT alone, it suggests the tumor might have been deemed unresectable initially or the patient opted against surgery. However, adenoid cystic carcinomas are often treated with surgery followed by adjuvant RT when feasible. The absence of chemo aligns with typical protocols for this histology, which is less responsive to chemotherapy.\n\nThe current opinions from other specialists (radiation oncologist) indicate a favorable outcome. But given the slow-growing nature of adenoid cystic carcinoma, long-term follow-up is crucial. Since both existing opinions agree, and as a surgeon, I might not need additional input unless there's a question about surgical options now or in recurrence. However, since the team already has consensus and no surgical intervention was part of the initial plan, consulting another expert might not be necessary unless new issues arise.",
        "Round 2-Turn 1-Round 2-Turn 1-gap_recruited_discuss-participate-ent surgeon": "Answer:Alive",
        "Round 2-role-comment": "radiation oncologist:alive|ent surgeon:alive",
        "Round 2-num_agents": 2,
        "num_cooperations-panel": 0,
        "decision-Moderator": "(radiation oncologist): Answer: Alive\n(ent surgeon): Answer: Alive\n\n('Answer: Alive',)"
    }
}